WALTHAM, Mass. and BEVERLY HILLS, Calif., March 30, 2021 /PRNewswire/ -- CorEvitas and
The Guthy-Jackson Charitable Foundation (GJCF) are excited to
announce plans for launching the SPHERES (Synergy of
Prospective Health & Experimental
Research for Emerging Solutions in NMOSD)
Registry for Neuromyelitis Optica Spectrum Disorder (NMOSD).
CorEvitas is the leading sponsor of registries in autoimmune and
inflammatory diseases. In collaboration with GJCF, the SPHERES
Registry is designed to better understand the benefit and safety of
newly approved therapies for patients diagnosed with NMOSD.
"The SPHERES Registry will serve as a comprehensive real-world
study to advance our knowledge of NMOSD in ways that directly help
patients. Importantly, its focus will include safety and
effectiveness of newly approved medications, evolving treatment
patterns and access, and understanding patient experience over
time. The study will also enable research on cellular and
molecular biomarkers through collection of biospecimens," said Dr.
Michael Yeaman, Professor of
Medicine at the David Geffen School of Medicine at UCLA and Chair Medical Advisor to the Guthy-Jackson
Charitable Foundation.
NMOSD is a rare neuroinflammatory autoimmune disease of the
central nervous system, primarily targeting the optic nerves,
spinal cord and brain. It is currently estimated to afflict
approximately 15,000 people in the U.S. and hundreds of thousands
worldwide. Historically, this disease has imposed significant
physical and emotional disability and life-threatening outcomes.
Today, advances in diagnosis, biomarkers and newly
FDA-approved treatment options offer patients with NMOSD promise to
lessen or prevent disability and enhance quality of life.
"We are excited and truly honored to partner with GJCF on this
collaborative research initiative, further demonstrating our deep
commitment as a company to accelerating real-world evidence
generation in neurologic diseases," said Dr. Jeff Greenberg, Chief Medical Officer of
CorEvitas.
Scientific experts in clinical research, epidemiology and
biostatistics at CorEvitas will manage, operate and analyze data
from the SPHERES Registry. Advisors from GJCF will serve on the
scientific steering committee and facilitate state-of-the art
research, building on the success and insights generated by the
CIRCLES (Collaborative International Research
in Clinical and Longitudinal Experience for
NMOSD Studies) Registry. The SPHERES registry represents the
ongoing commitment of Genentech, a Member of the Roche
Group, to support collaborative programs that benefit people
living with NMOSD and their families. CorEvitas and GJCF look
forward to additional industry partners joining this collaboration
going forward. CorEvitas and GJCF are inviting sites and patients
to join the registry to reach an enrollment goal of approximately
750 NMOSD patients. To learn more about the SPHERES Registry, visit
https://www.corevitas.com/contact-us.
About The Guthy-Jackson Charitable Foundation
(GJCF)
Since 2008, The Guthy-Jackson Charitable
Foundation has dedicated more than $65 million to funding
clinical and basic science research aimed at understanding and
solving NMOSD. As part of its field-transforming blueprint,
GJCF designed and led the CIRCLES Registry, created the
International Clinical Consortium for NMOSD including more than 100
world experts from 32 countries, formed the NMOSD Industry Council,
organized the International Panel on NMOSD Diagnosis, engaged FDA
in support of new therapies, and published a body of high-impact
papers in leading journals, among other high-impact
initiatives. As a result, the first-ever approved NMOSD
therapies — along with quantum leaps in patient quality of life,
improved diagnostics, biomarker identification, advances in
epidemiology, and pioneering tolerization clinical trials—are now
realities. The GJCF passionately supports programs that
elevate public awareness of NMOSD through education and advocacy
for patients, caregivers and healthcare providers. Together with
its partners, these breakthroughs exemplify the GJCF mission to
minimize the burden of NMOSD through prevention, rapid diagnosis,
safe and effective treatments, and ultimately cures for this
disease. Learn more at guthyjacksonfoundation.org.
About CorEvitasSM
CorEvitas is
the built-for-purpose gold-standard provider of real-world
evidence. Through syndicated registry data and analytic
services, CorEvitas helps biopharmaceutical companies demonstrate
the value of their products to clinicians, patients, payers, and
regulators. CorEvitas operates eight major autoimmune and
inflammatory registries across the US, Canada, and Japan, collecting data from nearly 500
participating investigator sites. In addition to supporting
hundreds of manuscripts and abstracts, CorEvitas has supported post
approval safety commitments for multiple newly approved treatments
in autoimmune diseases for both U.S. and European regulators.
CorEvitas is headquartered in Waltham,
MA. Its subsidiary, HealthiVibe, complements and strengthens
the company's strong presence in disease registries by providing
market-leading expertise in supporting innovative, evidence-based
patient engagement initiatives across the product lifecycle. The
HealthUnlocked technology platform hosts over 1.4 million patients
in hundreds of condition-specific communities and significantly
expands the scope of patient experiential data. Through Health iQ,
CorEvitas has access to a broad range of UK and international
data sets across primary and secondary care, as well as deep
relationships with the NHS and leading UK academic
institutions. CorEvitas is a portfolio company of Audax
Private Equity.
CONTACT INFORMATION:
CorEvitas, LLC
Erem Latif
+1 (508) 408-5529
elatif@corevitas.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/corevitas-and-the-guthy-jackson-charitable-foundation-announce-the-spheres-registry-a-new-research-study-benefitting-patients-with-nmosd-301257635.html
SOURCE CorEvitas